Yu Jiang

Yu Jiang

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 5723601
-
person_outline Yu Jiang's MOST POPULAR ARTICLES
1-) First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumorsJ Bendell, P LoRusso, M Overman, AM Noonan, DW Kim, JH Strickler, ...Cancer Immunology, Immunotherapy 72 (7), 2443-2458, 2023
2-) Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically …J Chastre, B François, M Bourgeois, A Komnos, R Ferrer, G Rahav, ...Critical care 26 (1), 355, 2022
3-) A phase 1b study to evaluate the safety and efficacy of durvalumab in combination with tremelimumab or danvatirsen in patients with relapsed or refractory diffuse large B-cell …V Ribrag, ST Lee, D Rizzieri, MJS Dyer, L Fayad, R Kurzrock, L Andritsos, ...Clinical Lymphoma Myeloma and Leukemia 21 (5), 309-317. e3, 2021232021
4-) 635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-Pseudomonas aeruginosa Bispecific Human Monoclonal Antibody in Mechanically …J Chastre, B François, M Bourgeois, A Komnos, R Ferrer, G Rahav, ...Open Forum Infectious Diseases 7 (Supplement_1), S377-S378, 2020202020
5-) General pharmacokinetic features of small‐molecule compounds exhibiting target‐mediated drug disposition (TMDD): a simulation‐based studyT Bach, Y Jiang, X Zhang, G AnThe Journal of Clinical Pharmacology 59 (3), 394-405, 2019132019